KaydedilenlerDerginizi ekleyin

Dergiler / Journal of critical and intensive care (Online) / 2020 / Cilt: 11 - Sayı: 1

Convalescent Plasma and Mesenchymal Stem Cell Therapy

Neriman Defne ALTINTAŞ
Sayfa
41–42
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, mesenchymal stem celltherapy for COVID-19 should only be considered in the context of a trial.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Since there are no currently accepted therapies for corona virus disease 2019 (COVID-2019), worldwidesearch for treatment options are ongoing.
📊
Temel Bulgular & Veri:Convalescent plasma therapy and mesenchymal stem cell therapyare considered as two of potential options.
💡
Sonuç & Katkı:However, mesenchymal stem celltherapy for COVID-19 should only be considered in the context of a trial.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Since there are no currently accepted therapies for corona virus disease 2019 (COVID-2019), worldwidesearch for treatment options are ongoing. Convalescent plasma therapy and mesenchymal stem cell therapyare considered as two of potential options. Convalescent plasma therapy may be recommended early duringthe course of severe or rapidly progressive illness, despite paucity of evidence. However, mesenchymal stem celltherapy for COVID-19 should only be considered in the context of a trial.

🔖

Bu Makaleye Atıf Yap

ALTINTAŞ, N. D. (2022). Convalescent Plasma and Mesenchymal Stem Cell Therapy. Journal of critical and intensive care (Online), Cilt: 11 - Sayı: 1, 41–42. https://ajindex.com/articles/562299

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;30(4):1545-1548 2. Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A Rapid Review. Cochrane Database Syst Rev. 2020 May 14;5:CD013600. doi: 10.1002/14651858.CD013600. 3. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility ofconvalescent plasma therapy in severe COVID-19 patients: apilot study. medRxiv 2020. 4. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020.4783. 5. Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015-19. 6. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü Kan ve Kan Ürünleri Dairesi Başkanlığı COVID-19 immün (konvalesan) plazma tedarik ve klinik kullanım rehberi, Nisan 2020 https://covid19bilgi. saglik.gov.tr 7. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216-228. 8. Metcalf SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Medicine in Drug Discovery. 2020;5:100019. 9. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician 2020; 23:E71-E83.